ReiThera and SillaJen Partner to Advance Novel Anticancer Virus Platform for Clinical Development
Italian CDMO ReiThera has established a strategic manufacturing partnership with SillaJen, marking a significant step forward in the development of innovative anticancer viral therapeutics. The comprehensive Master Service Agreement (MSA) positions ReiThera as the primary manufacturer for SillaJen's cutting-edge SJ-600 series anticancer virus platform.
The collaboration capitalizes on ReiThera's extensive experience in viral manufacturing, particularly their specialized knowledge of Vaccinia-based products, which forms the foundation of the SJ-600 series. As a Contract Development and Manufacturing Organization with decades of expertise in antinfective vaccines, cancer vaccines, and gene therapies, ReiThera will oversee both advanced development and GMP production of the therapeutic platform.
Technical Innovations in Cancer Treatment
The SJ-600 series represents a significant advancement in anticancer viral therapy, developed through a collaborative effort between the SillaJen Research Institute and Professor Lee's team at Seoul National University College of Medicine. The platform incorporates several innovative features that address key challenges in cancer treatment.
A notable technological breakthrough is the platform's ability to enable repeated administration without triggering neutralization reactions, a common limitation in viral therapeutics. Furthermore, the system expresses CD55, a complement regulatory protein, on the viral surface, significantly enhancing intravenous delivery capabilities and potentially improving therapeutic outcomes.
Manufacturing Strategy and Future Prospects
"Through collaboration with ReiThera, which has international vaccine development experience and the latest facilities, we are now able to promote standardized mass production of the SJ-600 series," stated Sillajen Chief Executive Officer, Jang Dong-taek. He emphasized that this partnership marks a crucial milestone, adding, "This indicates that we have entered a further stage for licensing out the SJ-600 series."
The manufacturing agreement is designed to transform the SJ-600 series into a clinical-ready drug product, preparing it for upcoming clinical trials. ReiThera's state-of-the-art facilities and proven track record in viral manufacturing are expected to play a crucial role in standardizing the production process and ensuring consistent quality for clinical development.